Early research (Phase 1)Study completedNCT02219711What this trial is testingPhase 1/1b Study of MGCD516 in Patients With Advanced CancerWho this might be right forAdvanced Cancer Mirati Therapeutics Inc. 193
Testing effectiveness (Phase 2)Ended earlyNCT05176925What this trial is testingTislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCWho this might be right forNon-small Cell Lung Cancer Fudan University 5
Testing effectiveness (Phase 2)Ended earlyNCT04925986What this trial is testingSitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCWho this might be right forCarcinoma, Non-Small-Cell LungLung DiseasesLung Neoplasms+6 more Sarah Goldberg 9
Testing effectiveness (Phase 2)UnknownNCT05228496What this trial is testingInvestigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCWho this might be right forLung Cancer, Small Cell Zhejiang Cancer Hospital 21
Early research (Phase 1)Study completedNCT03666143What this trial is testingA Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumors BeiGene 216
Testing effectiveness (Phase 2)Active Not RecruitingNCT04727996What this trial is testingPhase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerWho this might be right forAdvanced Biliary Tract Cancer Seoul National University Hospital 43
Testing effectiveness (Phase 2)WithdrawnNCT05419817What this trial is testingPembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair SystemWho this might be right forRecurrent Endometrial CancerSolid Tumors Haider Mahdi
Testing effectiveness (Phase 2)Study completedNCT02978859What this trial is testingSitravatinib in Advanced Liposarcoma and Other Soft Tissue SarcomasWho this might be right forLiposarcomaMetastatic Liposarcoma Columbia University 29
Testing effectiveness (Phase 2)Looking for participantsNCT05407519What this trial is testingEvaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionWho this might be right forHepatocellular Carcinoma Anhui Provincial Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT05461794What this trial is testingStudy To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaWho this might be right forEsophageal Squamous Cell Carcinoma BeiGene 96
Large-scale testing (Phase 3)Study completedNCT04887870What this trial is testingStudy of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyWho this might be right forAdvanced or Metastatic Solid Malignancies Mirati Therapeutics Inc. 52
Testing effectiveness (Phase 2)Study completedNCT03680521What this trial is testingNeoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaWho this might be right forClear Cell Renal Cell Carcinoma Mirati Therapeutics Inc. 25
Large-scale testing (Phase 3)Ended earlyNCT04921358What this trial is testingTislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer (NSCLC) BeiGene 377
Testing effectiveness (Phase 2)UnknownNCT05104801What this trial is testingSitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaWho this might be right forMelanoma Peking University Cancer Hospital & Institute 37
Testing effectiveness (Phase 2)UnknownNCT04734262What this trial is testingA Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Who this might be right forMetastatic Breast Cancer Fudan University 98
Testing effectiveness (Phase 2)Study completedNCT05542342What this trial is testingSitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.Who this might be right forUveal Melanoma Grupo Español Multidisciplinar de Melanoma 16
Early research (Phase 1)Study completedNCT04472650What this trial is testingRelative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsWho this might be right forTumor BeiGene 26
Testing effectiveness (Phase 2)Study completedNCT03941873What this trial is testingInvestigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerWho this might be right forCarcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer BeiGene 111
Early research (Phase 1)Study completedNCT05255276What this trial is testingPK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.Who this might be right forHealthy Adults Mirati Therapeutics Inc. 36
Testing effectiveness (Phase 2)Ended earlyNCT03606174What this trial is testingSitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaWho this might be right forUrothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more Mirati Therapeutics Inc. 260